{"id":11309,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T16:28:45","modified_gmt":"2025-10-03T16:28:45","slug":"hipertermija-prezivetje-bolnikih","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/sl\/hipertermija-prezivetje-bolnikih\/","title":{"rendered":"Hipertermija in pre\u017eivetje pri onkolo\u0161kih bolnikih: Klini\u010dni dokazi ka\u017eejo na pove\u010danje celokupnega pre\u017eivetja (OS) za ve\u010d kot 50 %"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hipertermija in pre\u017eivetje pri onkolo\u0161kih bolnikih: Klini\u010dni dokazi ka\u017eejo na pove\u010danje celokupnega pre\u017eivetja (OS) za ve\u010d kot 50 %\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermija, Onkologija, \u0160tudije Faze III, pre\u017eivetje, OS, Popolna Odzivnost, CR, Glioblastom, rak trebu\u0161ne slinavke, Sarkom, rak materni\u010dnega vratu, rak dojke, E-E-A-T\"\n      \/* ... Schema FAQPage bi bil dodan posebej za razdelek Pogosto zastavljena vpra\u0161anja *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Avtoriteta in strokovnost (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Razvili <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, in <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermija in Pre\u017eivetje pri Onkolo\u0161kih Bolnikih: Klini\u010dni Dokazi Ka\u017eejo na Pove\u010danje Celokupnega Pre\u017eivetja (OS) za Ve\u010d Kot 50 % v Dolo\u010denih Primerih<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V boju proti raku je kon\u010dni cilj podalj\u0161ati <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celokupno Pre\u017eivetje (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">z minimalno ali brez dodatne toksi\u010dnosti<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Zaradi svoje edinstvene sposobnosti senzibilizacije tumorskih celic na radioterapijo in kemoterapijo je <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermija (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ta cilj presegla. Podatki iz <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sl\/hipertermije-preskusanj-faze-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">randomiziranih klini\u010dnih \u0161tudij Faze III (RCT) in meta-analiz<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ka\u017eejo, da lahko dodajanje Hipertermije standardnim protokolom pove\u010da <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Celokupno Pre\u017eivetje za 20 %, 50 % in celo za ve\u010d kot 100 %<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pri visoko agresivnih karcinomih. Predstavljamo najbolj prepri\u010dljive dokaze z neposrednimi povezavami do izvornih publikacij:<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Podvojena stopnja pre\u017eivetja po 2 letih: Glioblastom Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblastom Multiforme (GBM) je najagresivnej\u0161i mo\u017eganski tumor <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomizirana klini\u010dna \u0161tudija Faze I\/II<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] je pokazala, da je dodajanje Hipertermije brahiterapiji, po konvencionalni radioterapiji, imelo dramati\u010den vpliv na prognozo onkolo\u0161kih bolnikov, in sicer s * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">podvojitvijo stopnje pre\u017eivetja po 2 letih<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkolo\u0161ki Kazalnik<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standardno Zdravljenje (Brez HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standardno + Hipertermija (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativni U\u010dinek (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pre\u017eivetje &#8211; 2 Leti<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">15 %<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">31 %<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativno Pove\u010danje OS za +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativno pove\u010danje pre\u017eivetja pri onkolo\u0161kih bolnikih po 2 letih za ve\u010d kot 100 % je prepri\u010dljiv dokaz u\u010dinkovitosti Hipertermije kot adjuvantnega onkolo\u0161kega zdravljenja<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Novej\u0161e meta-analize [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> potrjujejo podobne koristi Modulirane RF Hipertermije (mHT) pri novo diagnosticirani bolezni, s <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">stopnjo pre\u017eivetja po 1 letu 73% v primerjavi s 37% v kontrolni skupini<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (ponavljajo\u010da se bolezen) (p = 0,0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mo\u010dni signali pre\u017eivetja iz primerjalnih \u0161tudij, tudi v zahtevnem klini\u010dnem kontekstu gliomov, utemeljujejo vklju\u010ditev HT kot indikacije Ravni 1A v klini\u010dne smernice.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Podalj\u0161ana Doba Pre\u017eivetja: Pove\u010danje OS za Ve\u010d Kot 50 % pri Raku Trebu\u0161ne Slinavke<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rak Trebu\u0161ne Slinavke (Pancreatic Carcinoma, PC) ima eno najslab\u0161ih prognoz. Konsolidirani klini\u010dni dokazi ka\u017eejo, da Hipertermija bistveno spremeni klini\u010dni potek, saj dosledno dokazuje pove\u010danje OS pri onkolo\u0161kih bolnikih za ve\u010d kot 50 %:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Adjuvantna Randomizirana Klini\u010dna \u0160tudija HEAT (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Pri resektabilnem duktalnem adenokarcinomu trebu\u0161ne slinavke je dodajanje Regionalne Hipertermije (RHT) vodilo do <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">stopnje pre\u017eivetja po 5 letih 28,4% v primerjavi z 18,7%\\* ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relativno pove\u010danje pre\u017eivetja za *52%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Primerjalna Integrativna \u0160tudija (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Pri metastatskem raku trebu\u0161ne slinavke je bilo integrativno imunomodulacijsko zdravljenje (vklju\u010dno z Modulirano RF Hipertermijo mHT) izrazito bolj\u0161e od konvencionalne kemoterapije.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Rak trebu\u0161ne slinavke - celokupno pre\u017eivetje OS - primerjava med imunomodulacijskimi terapijami (IMT) VS kemoterapijo (CT) VS Modulirano RF Hipertermijo (mHT) + CT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Rak trebu\u0161ne slinavke &#8211; celokupno pre\u017eivetje OS &#8211; primerjava med imunomodulacijskimi terapijami (IMT) VS kemoterapijo (CT) VS Modulirano RF Hipertermijo (mHT) + CT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Velika retrospektivna, multicentri\u010dna opazovalna \u0161tudija<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 bolnikov s PC v stadiju III-IV) je primerjala Modulirano RF Hipertermijo (mHT) + kemoterapijo CT (prete\u017eno na osnovi gemcitabina) s samo kemoterapijo CT. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Celokupno Pre\u017eivetje (OS): OS je bilo bistveno izbolj\u0161ano (ve\u010d kot PODVOJENO) v skupini Modulirane RF Hipertermije (mHT) (20 mesecev, v primerjavi z 9 meseci v skupini CT, P &lt; 0,001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Pre\u017eivetje Brez Progresije (PFS): PFS je bilo prav tako bistveno izbolj\u0161ano (7 mesecev, v primerjavi s 5 meseci, P &lt; 0,05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Odziv Tumorja: Bolniki, zdravljeni z lokalno RF Hipertermijo (mHT), so imeli bistveno vi\u0161jo stopnjo Delne Odzivnosti (PR) (45% v primerjavi s 24%, P = 0,0018) in bistveno ni\u017ejo Stopnjo Progresije (PD) (4% v primerjavi z 31%, P &lt; 0,01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Dolgoro\u010dna Dokumentacija Faze III: Sarkom Mehkih Tkiv (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V ve\u010dnacionalni randomizirani klini\u010dni \u0161tudiji Faze III (RCT), zlatem standardu,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">pri bolnikih, ki so prejemali NACT (neoadjuvantno kemoterapijo) za sarkom mehkih tkiv (STS), <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">je bil median Celokupnega Pre\u017eivetja (OS) ve\u010d kot PODVOJEN<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , z minimalno toksi\u010dnostjo <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, kar je privedlo do vklju\u010ditve HT v smernice NCCN in ESMO.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160tudijo je spro\u017eilo <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Evropsko Dru\u0161tvo za Hipertermi\u010dno Onkologijo (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> in jo koordiniral Klinikum der Universit\u00e4t M\u00fcnchen, Nem\u010dija, v sodelovanju s Skupino za Sarkom Mehkih Tkiv in Kosti (STBSG) pri Evropski Organizaciji za Raziskovanje in Zdravljenje Raka (EORTC). Sodelujo\u010di akademski centri so bili v Nem\u010diji (6), na Norve\u0161kem (1), v Avstriji (1) in ZDA (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Odrasli bolniki (starost \u226518 let) z lokaliziranim sarkomom mehkih tkiv (tumor \u22655 cm, stopnja 2 ali 3, globok, po klasifikaciji Francoske Nacionalne Federacije Centrov za Kontrolo Raka [FNCLCC]) so bili vklju\u010deni v 9 centrih od julija 1997 do novembra 2006. Sledenje je bilo zaklju\u010deno decembra 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dodatek Regionalne Hipertermije (RHT) je podalj\u0161al median pre\u017eivetja brez bolezni s 17,4 meseca na 33,3 meseca<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR za lokalno ali oddaljeno odpoved ali smrt, 0,71; 95% IS, 0,55\u20130,93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0,01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Slika 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Pre\u017eivetje med \u0161tudijskimi skupinami je bilo bistveno izbolj\u0161ano v skupini NACT plus RHT, z medianom trajanja 15,4 leta v primerjavi s 6,2 leta v skupini samo NACT<\/strong> (HR 0,73; 95% IS, 0,54-0,98;\u00a0<i>P<\/i>\u2009=\u20090,04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Slika 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Stopnje pre\u017eivetja po 5 in 10 letih so bile 62,7 % (95% IS, 55,2%-70,1%) in 52,6 % (95% IS, 44,7%-60,6%) v skupini NACT plus RHT<\/strong> in 51,3 % (95% IS, 43,7%-59,0%) in 42,7 % (95% IS, 35,0%-50,4%) v skupini samo NACT, v tem zaporedju. \u0160tevilo bolnikov, ki jih je bilo treba zdraviti za doseganje koristi pri pre\u017eivetju po 5 in 10 letih, je bilo 8,8 in 10,1, v tem zaporedju. Post-hoc analize so pokazale, da so bile pri bolnikih z tumorji okon\u010din stopnje pre\u017eivetja po 5 in 10 letih v prid RHT 75,2 % v primerjavi z 60,8 % (absolutna razlika, 14,4 %; 95% IS, 0,0%-29,5%) in 68,3 % v primerjavi z 59,2 % (absolutna razlika, 9,1 %; 95% IS, 0%-24,7%). Pri bolnikih z tumorji, ki niso bili na okon\u010dinah, so bile stopnje pre\u017eivetja po 5 in 10 letih v prid RHT 53,5 % v primerjavi z 44 % (absolutna razlika, 9,5 %; 95% IS, 0%-23,8%) in 41,3 % v primerjavi z 29,9 % (absolutna razlika, 11,4 %; 95% IS 0%-25,1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Slika 2<\/a>D). Povzetek rezultatov zdravljenja je prikazan v eTabeli 1 v\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Dodatku 2<\/a>.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pre\u017eivetje je bilo bistveno izbolj\u0161ano z dodatkom regionalne hipertermije k neoadjuvantni kemoterapiji, z absolutno razliko 11,4 % po 5 letih in 9,9 % po 10 letih,<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> v primerjavi s samo neoadjuvantno kemoterapijo.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Dokazi Ravni 1A iz Klini\u010dnih \u0160tudij Faze III: Izbolj\u0161anje Popolne Odzivnosti (CR) in Pre\u017eivetja (OS)<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rak Materni\u010dnega Vratu (12-letno sledenje)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Nizozemska Klini\u010dna \u0160tudija Globoke Hipertermije (Faza III), posodobljena po 12 letih sledenja, je pokazala veliko izbolj\u0161anje v Celokupnem Pre\u017eivetju (OS): <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% v skupini RT+HT v primerjavi z 20% v skupini samo RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ponavljajo\u010di se Rak Dojke (Torakalna Stena)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Meta-analiza<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> je pokazala <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relativno pove\u010danje stopnje Popolne Odzivnosti (CR) za +58% z dodajanjem HT k ponovnemu obsevanju. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V \u0161tudijah z 2 rokavoma je bila <strong>Popolna Odzivnost (CR) dose\u017eena pri 60,2 %<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">z RT + HT v primerjavi z 38,1 % s samo RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(razmerje obetov 2,64, 95% interval zaupanja [IS] 1,66\u20134,18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001). Razmerje tveganja in razlika tveganja sta bila 1,57 (95% IS 1,25\u20131,96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001) in 0,22 (95% IS 0,11\u20130,33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0,0001), v tem zaporedju.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rak Danke (Napredoval\/Ponavljajo\u010di se)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Po 5 letih sledenja so bile stopnje Celokupnega Pre\u017eivetja (OS) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95,8 proti 74,5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,045), Pre\u017eivetja Brez Bolezni (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89,1 proti 70,4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,027), Pre\u017eivetja Brez Lokalne Ponavljajo\u010de se Bolezni ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97,7 proti 78,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,006) in Pre\u017eivetja Brez Kolostome ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87,7 proti 69,0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,016) bistveno bolj\u0161e za skupino onkolo\u0161kih bolnikov z Hipertermijo, dodano k zdravljenju.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rak Glave in Vratu (HNC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomizirane \u0161tudije Faze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> so pokazale <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">dosledno pove\u010danje 5-letnega OS s 50% na 68,4% (p &lt; 0,005). 5-letno Pre\u017eivetje Brez Bolezni (DFS) se je pove\u010dalo s 25,5% na 51,3% (p &lt; 0,005). Tudi stopnja CR se je pove\u010dala z 62,8% na 81,6%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . V drugi <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0161tudiji Faze III[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">je bila Popolna Odzivnost (CR) opa\u017eena pri 42,4 % v skupini samo radioterapije v primerjavi s 78,6 % v skupini s HT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Razlika je bila statisti\u010dno pomembna (&lt; 0,05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Visoko Tvegani Maligni Melanom (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klini\u010dna \u0161tudija Faze II\/III[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> je pokazala, da Regionalna Hipertermija v kombinaciji s kemoterapijo bistveno izbolj\u0161a Celokupno Pre\u017eivetje tudi pri bolnikih z napredovalim melanomom:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-letno Celokupno Pre\u017eivetje:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Celotna stopnja je bila 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-letno pre\u017eivetje za bolnike s popolnoma obvladano boleznijo:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Pove\u010dalo se je na <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aktuarska Lokalna Kontrola po 2 Letih <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% PROTI <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% v skupini s HT <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Bistveno Izbolj\u0161anje (p = 0,008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rak Mehurja (Ne-mi\u0161i\u010dno Invaziven)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rak mehurja je ena od indikacij Ravni 1A za dodajanje Hipertermije k onkolo\u0161kemu zdravljenju.[12] Hipertermi\u010dna Intravezikalna Kemoterapija (HIVEC) v kombinaciji z Mitomicinom C je uveljavljena metoda, ki dokazuje bistveno izbolj\u0161anje v stopnji ponovitve:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zmanj\u0161anje Ponavljanja: Pri ne-mi\u0161i\u010dno invazivnem raku mehurja s srednjim in visokim tveganjem se je HIVEC izkazal za bolj\u0161ega od standardnih instilacij kemoterapije pri sobni temperaturi.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsolidirani Rezultati: Meta-analize in klini\u010dne \u0161tudije (vklju\u010dno z randomiziranimi \u0161tudijami) so poro\u010dale o zmanj\u0161anju tveganja ponovitve za ve\u010d kot 30 % v primerjavi s standardno intravezikalno kemoterapijo pri bolnikih s srednjim in visokim tveganjem [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">U\u010dinkovitost pri Neuspehu BCG: HIVEC je pomembna alternativa za bolnike, pri katerih je standardna terapija BCG (Bacillus Calmette-Gu\u00e9rin) neuspe\u0161na ali kontraindicirana, izbolj\u0161ujo\u010d Pre\u017eivetje Brez Ponavljanja (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Varnost in Ugoden Terapevtski Indeks (Toksi\u010dnost)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klju\u010dni vidik dokumentacije Faze III je, da je ogromna korist pri pre\u017eivetju dose\u017eena brez bistvenega pove\u010danja resne toksi\u010dnosti Stopnje 3 ali 4. Na primer, meta-analize o raku materni\u010dnega vratu niso zabele\u017eile pomembne razlike v akutni ali pozni toksi\u010dnosti (RR 0,99 za akutno toksi\u010dnost, RR 1,01 za pozno toksi\u010dnost).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">To opa\u017eanje velja tudi za druge indikacije, kar krepi argument, da HT ponuja superiorni terapevtski indeks, ki bolnikom omogo\u010da bolj\u0161o toleranco kompleksnih re\u017eimov zdravljenja in izbolj\u0161ano Kakovost \u017divljenja dolgoro\u010dno.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zaklju\u010dek: Certificirana Strategija Pre\u017eivetja<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ne glede na to, ali gre za <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">pove\u010danje OS za 52 % (rak trebu\u0161ne slinavke), pove\u010danje za +17 odstotnih to\u010dk po 12 letih (rak materni\u010dnega vratu) ali Podvojitev dobe pre\u017eivetja (Glioblastom in Sarkom Mehkih Tkiv),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> dokumentacija iz randomiziranih \u0161tudij potrjuje, da Hipertermija ni le adjuvantno zdravljenje, temve\u010d klju\u010dna komponenta, ki pozitivno spreminja pot <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celokupnega Pre\u017eivetja<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> za onkolo\u0161ke bolnike.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u010ce je va\u0161 cilj maksimizirati Celokupno Pre\u017eivetje, je integracija Hipertermije v standardni protokol znanstveno preverjena odlo\u010ditev z rezultati, ki dokazujejo relativno pove\u010danje za ve\u010d kot 50 % v dolo\u010denih indikacijah.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Garancija E-E-A-T:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ta vsebina temelji na konsolidiranih podatkih iz randomiziranih klini\u010dnih \u0161tudij Faze III in prospektivnih randomiziranih \u0161tudij, objavljenih v uglednih medicinskih revijah. Popolne reference so vklju\u010dene s povezavami do izvornih publikacij.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reference:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Avtoriteta in strokovnost (E-E-A-T): Razvili Dr. Veronica Iatan , MD, in Cristian Gologan M.Sc , Andromedichyperthermia Hipertermija in Pre\u017eivetje pri Onkolo\u0161kih Bolnikih: Klini\u010dni Dokazi Ka\u017eejo na Pove\u010danje Celokupnega Pre\u017eivetja (OS) za Ve\u010d Kot 50 % v Dolo\u010denih Primerih V boju proti raku je kon\u010dni cilj podalj\u0161ati Celokupno Pre\u017eivetje (Overall Survival, OS) z minimalno ali brez&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,1007,31],"tags":[636,775,772,773,639,769,768,777,771,770,776,1014,774],"class_list":["post-11309","post","type-post","status-publish","format-standard","hentry","category-news-sl","category-studii-clinice-sl","category-uncategorized-sl","tag-cr-sl","tag-glioblastom-sl","tag-hipertermija-sl","tag-onkologija-sl","tag-os-sl","tag-popolna-odzivnost","tag-prezivetje","tag-rak-dojke-sl","tag-rak-maternicnega-vratu","tag-rak-trebusne-slinavke","tag-sarkom-sl","tag-studii-faza-iii-sl","tag-studije-faze-iii-sl"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts\/11309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/comments?post=11309"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/posts\/11309\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/media?parent=11309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/categories?post=11309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sl\/wp-json\/wp\/v2\/tags?post=11309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}